Just over one year has passed since the authorization of first-generation vaccines against COVID-19. Since then, almost 10 billion doses of COVID-19 vaccines have been administered globally.
Although the delivery of this number of vaccines is a remarkable achievement, there is still a disparity in vaccine equity, access, and affordability between high-income and low-income countries. According to the Global Dashboard for Vaccine Equity (established by the UN Development Programme, WHO, and the University of Oxford), as of Jan 18, 2022, approximately 67.6% of people in high-income countries have had at least one dose, compared with only approximately 11.36% of people in low-income countries.
This inequity has major negative implications for global pandemic control; thus, there is an imperative to develop more affordable, scalable, and easily distributable vaccines.
In the current landscape of mRNA, viral vector, and inactivated COVID-19 vaccines, one modality that has been largely under-represented is DNA vaccines.
You can read more at…..DNA vaccines join the fight against COVID-19 – PubMed (nih.gov)
In addition, for daily updates on the pandemic, the global dissemination of cases and the vaccine progress, you can visit the following websites:
https://coronavirus.jhu.edu/map.html
or
https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
Disclaimers
- The material in these reviews is from various public open access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
